This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through March 4, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Select Medical (SEM) Expands in Florida With UF Health JV
by Zacks Equity Research
Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.
Select Medical's (SEM) Concentra Submits Confidential IPO Filing
by Zacks Equity Research
The move from Select Medical's (SEM) Concentra highlights the recovery in the U.S. IPO market, especially for healthcare companies.
The Joint Corp. (JYNT) Moves 10.1% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Acadia Healthcare (ACHC) Q4 Earnings Beat on Strong Admissions
by Zacks Equity Research
Acadia Healthcare's (ACHC) Q4 results gain on strong growth in revenue per patient day. It expects adjusted EPS of $3.40-$3.70 for 2024, the mid-point of which implies a 3.2% rise from the 2023 reported figure.
Select Medical (SEM) Q4 Earnings Beat on Patient Admissions
by Zacks Equity Research
Select Medical's (SEM) Q4 results reflect strong segmental contribution, aided by higher patient days and visits. Management expects 2024 adjusted EBITDA to be $830-$880 million, up from the 2023 reported figure of $807.4 million.
Select Medical (SEM) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Select Medical (SEM) delivered earnings and revenue surprises of 16.13% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
by Zacks Equity Research
Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.
Select Medical (SEM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Molina (MOH) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 1.62% and 8.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of -57.14% and 1.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Select Medical (SEM): Can Its 11.3% Jump Turn into More Strength?
by Zacks Equity Research
Select Medical (SEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Select Medical (SEM) Unveils Separation Plan for Concentra
by Zacks Equity Research
Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
Why Select Medical (SEM) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Select Medical (SEM) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Select Medical (SEM) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Select Medical (SEM) Stock Down 6.6% Despite Q3 Earnings Beat
by Zacks Equity Research
Select Medical (SEM) continues to expect adjusted EBITDA to be between $795 million and $825 million in 2023.
Zacks.com featured highlights Select Medical, PVH, Centene, Paysafe and HF Sinclair
by Zacks Equity Research
Select Medical, PVH, Centene, Paysafe and HF Sinclair have been highlighted in this Screen of The Week article.
Zacks.com featured highlights include Select Medical Holdings, Hibbett, PVH and Centene
by Zacks Equity Research
Select Medical Holdings, Hibbett, PVH and Centene are part of the Zacks Screen of the Week article.
5 Low Price-to-Book Stocks to Buy in November
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks that have high growth prospects. Select Medical Holdings Corporation (SEM), PVH Corp. (PVH), Centene (CNC), Paysafe Limited (PSFE) and HF Sinclair Corporation (DINO) are some such stocks.
Give Your Investments a Boost With These 4 Low P/CF Stocks
by Sumit Singh
Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Select Medical (SEM), Hibbett (HIBB), PVH Corp. (PVH) and Centene Corporation (CNC) boast low P/CF ratios.
Humana (HUM) Q3 Earnings Beat on Strong Individual MA Unit
by Zacks Equity Research
Humana (HUM) continues to project 2023 adjusted EPS at a minimum of $28.25, which suggests growth from the 2022 figure of $25.88.
Universal Health (UHS) Q3 Earnings Beat on Adjusted Patient Days
by Zacks Equity Research
Universal Health (UHS) has a leftover repurchase capacity of around $580 million as of Sep 30, 2023.
Select Medical (SEM) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Select Medical (SEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.